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Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disease that is
characterized by the death of upper and lower motor neurons. Recent studies have made
it clear that although motor neurons are the primary targets of the degenerative process,
other cell types play key roles in the death of motor neurons. Most notably, cells of the
immune system, including astrocytes and microglia have come under increasing scrutiny,
after multiple lines of evidence have shown these cells to be deleterious to motor neurons.
Both in vitro and in vivo experiments have shown that astrocytes and microglia containing
mutated SOD1 are harmful to motor neurons. Several studies on ALS and other neurode-
generative diseases have revealed that reactive astrocytes and microglia are capable of
releasing pro-inflammatory factors such as cytokines and chemokines, which are harmful
to neighboring neurons. In addition, it is believed that diseased astrocytes can specifically
kill motor neurons through the release of toxic factors. Furthermore, in an animal model
of the disease, it has been shown that the reduction of SOD1 in microglia may be able
to slow the progression of ALS symptoms. Although the exact pathways of motor neuron
death in ALS have yet to be elucidated, studies have suggested that they die through aBax-
dependent signaling pathway. Mounting evidence suggests that neuroinflammation plays
an important role in the degeneration of motor neurons. Based on these findings, anti-
inflammatory compounds are currently being tested for their potential to reduce disease
severity; however, these studies are only in the preliminary stages. While we understand
that astrocytes and microglia play a role in the death of motor neurons in ALS, much work
needs to be done to fully understand ALS pathology and the role the immune system plays
in disease onset and progression.
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INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is a fatal adult-onset neu-
rodegenerative disorder that is characterized clinically by muscle
weakness and wasting. Pathologically, it is identified by the degen-
eration of upper and lower motor neurons (Boillee et al., 2006a).
Generally, death results from respiratory failure due to paralysis
of the respiratory muscles. The incidence of ALS is reported to
be between 1.5 and 3 per 100,000 in Europe and North America
(Wijesekera and Leigh, 2009; Hardiman et al., 2011). ALS onset
peaks between the ages of 50–75 and declines thereafter. These
factors suggest that ALS may not be a disease of aging, but rather
that age may be one of a multitude of contributing factors (Hardi-
man et al., 2011). Thus far, there are no effective treatments and
no cure for ALS.
Amyotrophic lateral sclerosis is essentially a sporadic disor-
der, with greater than 90% of the cases originating from an
unknown cause. However, approximately 10% of the cases are
considered familial (FALS) and are generally inherited as a dom-
inant disorder (Ince et al., 2011) due to mutations in a num-
ber of seemingly disparate genes. These include, but are not
limited to, mutations in genes such as TAR DNA binding pro-
tein (TDP)-43 and Fused in Sarcoma (FUS) (Sreedharan et al.,
2008; Kwiatkowski et al., 2009; Vance et al., 2009). Despite major
enthusiasm by the research community about the recent discov-
eries of mutations in FUS and TDP-43, the best characterized
form of FALS still remains that which is linked to mutations in
the copper-zinc superoxide dismutase gene (SOD1) and which
accounts for 10–20% of all FALS cases (Andersen, 2001). Myr-
iad mutations in SOD1 all seem to give rise to an ALS pheno-
type via a toxic gain-of-function mechanism, which is clinically
almost indistinguishable from sporadic cases. Histopathologi-
cally, however, recent studies have found TDP-43 to be a reli-
able marker for differentiating sALS from SOD1-related fALS.
These studies have shown that all of the cases of sporadic ALS
and SOD1-negative fALS had neural and glial inclusions which
were immunoreactive for both ubiquitin and TDP-43, whereas
fALS cases with mutations in SOD1 were universally absent of
TDP-43 immunoreactivity (MacKenzie et al., 2007; Tan et al.,
2007).
More recently, studies have identified an expanded GGGGCC
hexanucleotide repeat in a non-coding region of C9ORF72. This
expansion has been shown to be linked to chromosome 9p-
linked FTD and ALS. Interestingly, this same repeat expansion
was also identified in the majority of families with a combined
FTD/ALS phenotype and TDP-43 pathology. Extended studies
have identified the C9ORF72 expansion as the most common
www.frontiersin.org August 2012 | Volume 3 | Article 150 | 1
Phani et al. The role of the innate immune system in ALS
genetic abnormality in fALS (23.5%; DeJesus-Hernandez et al.,
2011).
A number of studies have pointed to oxidative stress, pro-
tein aggregation, or mitochondrial dysfunction as mechanisms of
mutant SOD1 toxicity. In addition, SOD1 toxicity has been shown
to be linked to changes in the immune system, which has also
been shown to contribute to the motor neuron pathology seen in
ALS; however, the exact nature of the pathogenic mechanisms pro-
voking motor neuron degeneration in mutant SOD1-linked ALS
remains elusive (Ince et al., 2011). Interestingly, the repeat expan-
sion in C9ORF72 results in the formation of nuclear RNA foci
not seen in SOD1-linked pathology, suggesting multiple disease
mechanisms (DeJesus-Hernandez et al., 2011).
While the discovery of the C9ORF72 repeat expansion has
opened new avenues of ALS research, the abundance and well-
studied nature of SOD1-mutant animals make them the de
facto models of choice to study ALS pathology for the time
being. Although imperfect, these models allow for a great deal
of insight into potential mechanisms involved in ALS pathology,
with the hope that the mechanisms elucidated through the use
of these models may also provide understanding of sALS and
non-SOD1-mediated fALS.
INFLAMMATION AND NEURODEGENERATION
Although ALS is a disease primarily affecting upper and lower
motor neurons, it is increasingly recognized that the entire patho-
genic process of ALS is not restricted to a set of cell-autonomous
deleterious mechanisms taking place within motor neurons.
Instead, it is now believed that non-cell autonomous mechanisms,
such as neuroinflammation may also contribute to the disease
process.
Germane to this issue is the fact that the immune system has
been found to be altered in sporadic ALS. Studies have shown
immunological differences in the blood of ALS patients compared
to healthy controls. These include increased levels of CD4+ cells,
and reduced CD8+T-lymphocytes (Mantovani et al., 2009). Inter-
estingly, blood samples analyzed from patients at an earlier and
less severe stage of the disease also show altered expression of
immune cells, such as significant reductions in CD4+CD25+ T-
regulatory (T-reg) cells as well as CD14+monocytes (Mantovani
et al., 2009). Additionally, T-reg cells have been shown to play sig-
nificant roles as neuroprotectants responsible for modulating the
neuroinflammatory response in mouse models of neurodegenera-
tion (Kipnis et al., 2004). It is therefore possible to hypothesize that
the reduction of T-reg cells in the blood of sporadic ALS patients
might represent a recruitment of these cells from the periph-
ery into the CNS in order to activate resident innate immune
cells such as microglia, as well as anti-inflammatory cytokines
such as interleukin-10 and transforming growth factor-β in an
effort to protect the area most affected by the early effects of ALS
degeneration (Kipnis et al., 2004; Mantovani et al., 2009).
Markers for resident innate immune cells have also been found
to be altered in the brains of ALS patients as well as in animal
models of ALS. For instance, immunostaining for glial fibril-
lary acid protein (GFAP), a common marker for astrocytes, is
markedly increased in all forms of ALS in the precentral gyrus of
human samples (Kawamata et al., 1992). In addition, staining for
leukocyte common antigen (LCA), lymphocyte function associate
molecule-1 (LFA-1), and complement receptors CR3 (CD11b) and
CR4 (CD11c) are increased, supporting the idea that microglia
and macrophages are activated in the areas of ALS degenera-
tion, such as the motor cortex, brainstem, and corticospinal tract
(Kawamata et al., 1992; Papadimitriou et al., 2010). Remarkably,
it is believed that the early site of pathological changes in ALS
is the neuromuscular junction, and while this particular site of
the lower motor neuron pathway has been extensively studied,
very little information exists about the immune response at that
level. Nonetheless, the data reviewed above provide compelling
evidence that a robust neuroinflammatory response is part of the
neuropathological changes that characterize ALS. However, none
of the aforementioned studies address the actual role, if any, of
neuroinflammation in ALS. Investigations in other neurodegener-
ative disorders have shown that neuroinflammation may exert dual
effects, that it can be protective or harmful. In order to distinguish
between these two possibilities, efforts have generally concentrated
on studying animal models of ALS.
The blood brain barrier renders the brain as immune-
privileged, therefore, the brain contains resident astrocytes and
microglia that perform the duties of immune surveillance and act
as an innate response system. Reactive astrocytes are most com-
monly recruited to the site of an injury, such as a spinal cord injury
or ischemic events. Their main functions are to compact inflam-
matory cells, and to re-establish the blood brain barrier (Okada
et al., 2006) they may also be involved in clearing CNS debris, such
as amyloid plaques (Papadimitriou et al., 2010). Aside from astro-
cytes, the CNS immune system also consists of ramified resting
microglial cells, whose processes play an active role in maintain-
ing the homeostasis of the neural environment. Once activated by
the presence of antigens and during times of distress, such as is
the case during neurodegeneration, microglia, like other immune
cells, become activated taking on an ameboid morphology. Once
activated, microglia can secrete a myriad of neurotrophic factors
and cytokines (Napoli and Neumann, 2009), and engage in the
clearance of pathogens and debris through phagocytosis. However,
unregulated activation of microglial activation may be harmful to
neurons through the release of potentially harmful neurotoxins
including quinolinic acid, reactive oxygen and nitrogen species
(ROS; RNS), and pro-inflammatory cytokines. Although a large
number of studies have shown that microglia and, to a lesser
extent, astrocytes are activated in the affected areas of the CNS
in ALS, thus far little attention has been paid to the determination
of the actual phenotype of these cells. For instance, since activated
resident immune cells can display either a pro-inflammatory or
anti-inflammatory phenotype, sometimes referred to as M1 or
M2, it will be critical to determine which phenotype they exhibit
as a whole, and if possible as individual cells. It is also important to
determine whether such profiles differ among the various affected
structures of the CNS and stages of the disease. Aside from these
outstanding questions, it is also critical to elucidate whether these
inflammatory cells play a role in the pathogenesis of ALS. The use
of animal models is greatly aiding in the attempts to answer the
questions raised by the findings described above.
The most commonly studied animal models of ALS are rats and
mice expressing mutant SOD1 (mSOD1). Although, as indicated
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above, SOD 1 mutations only account for a small percentage of
human cases, animal models using mSOD1 are used with the
hope that the mechanisms leading the disease are shared across
cases, and knowledge gained from these models can be used to
understand the development of the disease in humans. Notably,
evidence for increases in astrocytes and microglia have also been
found in transgenic mice expressing different forms of mutant
SOD1 (mSOD1), supporting human pathology studies (Fischer
et al., 2004). Specifically, GFAP and CD11b staining showed evi-
dence for significant increases in reactive astrocytes and microglia
in the motor regions of transgenic mice containing mSOD1 (Fis-
cher et al., 2004). Although both astrocytosis and microgliosis have
been observed in rodent models, the timing of events seems to be
unclear. Some studies using mSOD1 mice have suggested astro-
cytosis to be an early stage event, with microgliosis as a late stage
reaction (Yang et al., 2011). However, others have suggested that
microglial response occurs at a much earlier stage of the disease
(Sanagi et al., 2010). Nevertheless, it does appear that microglial
activation starts after motor neuron degeneration, and initially
tries to protect motor neurons from degeneration (Fischer et al.,
2004; Henkel et al., 2009).
IMMUNE CELL MEDIATED NON-CELL AUTONOMY IN ALS
Motor neuron death and degeneration has been implicated in
causing the debilitating symptoms characteristic of ALS, however,
mounting evidence indicates that motor neuron death is, at least
in part, non-cell autonomous. In vivo studies have shown that
mSOD1 expressed only in motor neurons of transgenic mice is
either not sufficient to cause neurodegeneration or causes only a
mild ALS-like phenotype (Jaarsma et al., 2008). Support for non-
cell autonomy comes from studies showing that when mSOD1
expression was reduced in microglia and macrophages in trans-
genic mice (Boillee et al., 2006b; Wang et al., 2009), motor neuron
degeneration was decreased. Aside from microglia, evidence has
shown that astrocytes may also play a role in motor neuron
death. Early studies using transgenic mice expressing mSOD1 in
astrocytes suggested the need for motor neurons to be impaired
for a degenerative phenotype (Gong et al., 2000), however more
recent studies have concluded that astrocytes expressing mSOD1
released toxic factor(s) which were sufficient to cause motor neu-
ron degeneration in an in vitro model of ALS (Nagai et al.,
2007).
THE ROLE OF ASTROCYTES IN ALS NON-CELL AUTONOMY
Astrocytes are one of the main cell types responsible for the clear-
ance of potentially excitotoxic glutamate from the synaptic space,
and as mentioned earlier, play a distinct role when they become
activated by the immune system. Quite interestingly, glutamate
handling has been reported to be modified in both sporadic and
familial ALS (Boillee et al., 2006a). Studies have found that brain
and spinal cord samples from ALS patients showed altered glu-
tamate transport (Rothstein et al., 1992) resulting from changes
in the glutamate transporter EAAT2 (Maragakis et al., 2004). Evi-
dence suggests that EAAT2 is significantly decreased in the motor
cortex and spinal cords of ALS patients (Fray et al., 1998), as well as
in the spinal cords of mSOD1 transgenic mice (Bruijn et al., 1997)
and rats (Howland et al., 2002). It should come as no coincidence
then, that astrocytes were quickly targeted for their role in the ALS
disease processes.
More interestingly in terms of inflammation, samples analyzed
from the brains and spinal cords of ALS patients were found to
contain greater numbers of activated or reactive astrocytes, a clear
sign of an immune response (Sta et al., 2011). Of note, and useful
for research purposes, increased reactive astrocyte expression has
been found both in ALS patients and in animal models of ALS (Sta
et al., 2011).
Although the main function of astrocytes in the synaptic
space is the maintenance of a homeostatic environment for neu-
rons though activities such as the clearance of neurotransmitters,
reactive astrocytes gain properties that resting astrocytes do not
exhibit. It has been shown that during and after injury, astrocytes
have the ability to ameliorate symptoms by physically isolating the
injured area through the formation of a glial scar, as well as release
neurotrophins and growth factors such as IGF-1 which have been
deemed beneficial to injured cells (Dong and Benveniste, 2001).
Astrocytes have also been found to release NGF and induce addi-
tional sprouting both in vitro and in vivo, a key step in neuronal
recovery (Chalmers et al., 1996; Wu et al., 1998).
Even though astrocytes do have the potential to be benefi-
cial to neurons, the majority of evidence suggests that astrocytes
actually contribute to neuronal degeneration during disease, with
ALS being no exception. Interestingly, NGF release, which has
generally been regarded as a positive attribute of reactive astro-
cytes, has been shown to directly lead to motor neuron apoptosis
through the p75 pathway (Pehar et al., 2004). Notably, mSOD1-
containing astrocytes have been found to be even more toxic to
their environments than reactive astrocytes alone. Studies have
found that reducing mSOD1 expressing astrocyte levels in an
in vivo model of ALS decreased motor neuron degeneration and
correspondingly increased the life span of the affected animals
(Lepore et al., 2008; Barbeito et al., 2010). Although the exact
mechanisms for astrocyte-mediated motor neuron toxicity is not
known, several lines of evidence have pointed to the activation
and release of toxic or harmful products such as pro-inflammatory
cytokine oxidative stressors. These include, but are not limited to
prostaglandins, leukotrienes, and RNS (Hensley et al., 2006a,b). In
addition, in vitro models of ALS have shown that astrocytes con-
taining mSOD1 release toxic factors that are preferentially toxic
to motor neurons. Furthermore, it was noted that even wild-
type motor neurons die in the presence of mSOD1-containing
astrocytes. Moreover, wild-type motor neurons die when grown
in media conditioned by mSOD1 containing astrocytes. These
in vitro studies have suggested the pro-apoptotic Bax pathway
as another mechanism through which astrocytes mediate motor
neuron cell death (Nagai et al., 2007).
THE ROLE OF MICROGLIA IN ALS
Microglial cells perform the duties of immune surveillance in the
CNS, and once activated, such as is the case during neurodegener-
ation, these cells secrete cytokines and neurotrophins in order to
help restore homeostasis to the neuronal environment (Napoli
and Neumann, 2009). However, just as astrocytes may play a
deleterious role in ALS, microglia have also been found to exac-
erbate neuronal injury. In vivo studies have shown that microglial
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cells increase their expression and release of pro-inflammatory
cytokines, such as TNF-α and IL-1β in a mouse model of ALS.
Additionally, activated microglia have been shown to promote the
generation of reactive oxidative species, causing more harm than
good to motor neurons (Henkel et al., 2009).
In the case of ALS, a number of studies have looked at mSOD1
expression in microglia, and its effect on ALS disease progression
and motor neuron degeneration. Recent studies have found that
diminishing mSOD1 levels in microglia in a mouse model of ALS
did not alter the age of onset of paralysis, however it was able to
significantly slow the disease progression (Boillee et al., 2006b).
Yet, the lack of effects on onset must be regarded with caution,
as one cannot exclude that the reduction in mSOD1 in microglia
was only at the time when some actual motor neuron degener-
ation has already occurred. Indeed, the technology used in this
study to reduce mSOD1 expression was driven by the microglial
specific promoter CD11b which only acquires significant driving
forces in response to pathological stimuli such as motor neuron
degeneration. Accordingly, it would not be surprising that the dis-
ease phenotype in these mice has only been modified after the
onset of motor neuron degeneration. It has also been found that
mSOD1 containing microglia produce and release greater levels
of pro-inflammatory cytokines and free radicals than their wild-
type counterparts (Henkel et al., 2009). While the presence of
mSOD1 in microglia has been shown to be deleterious, new evi-
dence has begun to pinpoint the mechanisms that may control
ALS-related microglial toxicity. Specifically, increases in the pro-
inflammatory cytokines and prostaglandin E2 have been reported
to be present in ALS patients (Papadimitriou et al., 2010). Addi-
tionally, in vitro data suggested that conditioned media obtained
from activated microglia is sufficient to cause neuronal degener-
ation through the concurrent stimulation of TNF-α and NMDA
receptors. These pathways are thought to up-regulate inducible
nitric oxide synthase activity, thus causing oxidative stress which
leads to cell death. Of note is the fact that activation of either the
TNF-α or NMDA receptor alone was not found to cause cell death,
and the blockade of either of these receptor pathways was found to
alleviate cell death caused by microglial-conditioned media, sug-
gesting that both of these receptors need to be activated for MN
death to occur (Moisse and Strong, 2006).
Although there is compelling evidence supporting the notion
that microglial activation could be sufficient to kill motor neu-
rons in ALS, in vivo studies have cast doubt on this theory by
showing that repopulating microglial-deficient mice with mSOD-
containing microglia failed to cause motor neuron death. These
studies have yet to be repeated (Boillee et al., 2006a,b). In addition,
studies done in mSOD1 mice absent in TNF-α, a potent inflam-
matory signaling molecule, did not show any decrease in motor
neuron death (Gowing et al., 2006). These data are perhaps sug-
gestive of alternate inflammatory pathways, and may implicate
inflammatory mechanisms as coincidental, but not causative.
When viewed together, mounting in vitro and in vivo evi-
dence have given credence to the toxic effects of astrocytes and
microglia on motor neurons and have suggested multiple mech-
anisms that may be involved. In addition to these, it must be
noted that mSOD1 containing motor neurons are particularly vul-
nerable to Fas ligand and NO-triggered cell death (Moisse and
Strong, 2006). Therefore, it is thought that the combined effects
of mSOD1 in motor neurons as well as in neighboring astrocytes
and microglia are what ultimately result in cell death and degen-
eration in ALS. While the discovery of the expansion repeat in
C9ORF72 is too recent to know its relationship with the inflam-
matory system, it would be conceivable that the immune system
response to such a widespread mutation would be equal to or
greater than what has already been observed in other forms of
ALS.
ANTI-INFLAMMATORY THERAPEUTICS IN ALS
With inflammation potentially playing a significant role in ALS
pathogenesis and progression, it is logical to attempt anti-
inflammatory drugs for use as therapeutics in combating ALS.
Using SOD1 mice, a number of groups have attempted to admin-
ister COX2 inhibitors such as cyclosporine, thalidomide, and
lenalidomide to COX2-deficient mice in order to attenuate the
negative effects of inflammation. Interestingly, the use of these
drugs in mSOD1 animal models was sufficient to prolong lifespan
(Karlsson et al., 2004; Kiaei et al., 2006). Cyclosporine is currently
in clinical trials. Initial double-blind, placebo-controlled clinical
trials suggest that men may benefit from cyclosporine adminis-
tration when given within 18 months of initial diagnosis (Appel
et al., 1988). Based on these results, the group of Karlsson et al. are
currently running Phase II clinical trials.
Another approach to anti-inflammatory therapy was the use
of the drug Copaxone, which has most often been used to treat
patients diagnosed with multiple sclerosis. The active ingredient,
glatiramer acetate, was used both in animal models as well as clin-
ical trials. While there was initial excitement for the drug, which
increased survival in mSOD1 mouse models of ALS (Angelov et al.,
2003), these results could not be replicated (Turner and Talbot,
2008). Clinical trials with glatiramer acetate were also unsuccessful
(Meininger et al., 2009), suggesting the mouse strain or the deliv-
ery mechanism in the original study may have played a greater role
than initially indicated.
Perhaps the most well-known of the anti-inflammatory com-
pounds used against ALS is minocycline, a second-generation
tetracycline which has been shown to have anti-inflammatory
properties (Yrjanheikki et al., 1999). The use of minocycline was
shown to delay motor neuron degeneration as well as increase sur-
vival in several different mSOD1 mouse models of ALS (Kriz et al.,
2002; Zhu et al., 2002). These studies found that minocycline may
have had a direct impact on motor neurons by decreasing apopto-
sis through a reduction in cytochrome c release (Zhu et al., 2002;
Moisse and Strong, 2006). Furthermore, it may have decreased the
level of microglial activation and proliferation in mSOD1 mouse
models of ALS (Kriz et al., 2002; Moisse and Strong, 2006). Given
these promising results, minocycline was moved into clinical trials,
and thus far, no observable difference was found between placebo
and drug cohorts in phase III trials (Barbeito et al., 2010).
It should be noted however, that the use of anti-inflammatory
drugs in animal models does not lead to direct knowledge of drug
dosing and further study may be needed in order to find correct
dosing levels, and potentially more importantly, dosing schedules.
The use of animal models allows researchers to administer thera-
peutics before, during, after, or any combination therein relative to
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symptom onset. Unfortunately, patients being treated for neurode-
generative disorders do not have the luxury of being pre-treated
for ALS symptoms before they arise, thus vastly complicating any
therapeutic regimen.
CONCLUSION
Recent lines of evidence have given strong support to the role of
astrocytes and microglia in ALS disease pathology. Tissue sam-
ples from ALS patients have been found to contain increased
inflammatory by-products, and animal models of ALS have cor-
roborated these increases. There is some debate as to whether
inflammation in ALS could potentially be protective, however
most studies have found the activation of microglia and astrocytes
to be more harmful than beneficial. These harmful effects may
come through the up-regulation and increased release of pro-
inflammatory cytokines and reactive oxidative species, as well as
through decreased uptake of excitotoxic neurotransmitters such
as glutamate from the synaptic space. One major unanswered
question, however, is whether an external event causes neuroin-
flammatory activation leading to ALS, or whether an external event
leads to ALS causing neuroinflammation. In either case, both ALS
pathology and neuroinflammation seem to act concurrently to
exacerbate the symptoms of neurodegeneration. Future therapies
to combat motor neuron death may involve a combination of
approaches which recognize the role of multiple mechanisms and
cell types in the progression of ALS.
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